Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CEO Sells 4,841 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 4,841 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $201,191.96. Following the transaction, the chief executive officer now directly owns 603,886 shares of the company’s stock, valued at approximately $25,097,502.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Twist Bioscience Price Performance

NASDAQ TWST traded up $2.28 on Wednesday, hitting $45.42. 1,019,545 shares of the stock were exchanged, compared to its average volume of 942,883. The company’s 50-day moving average price is $43.61 and its two-hundred day moving average price is $45.43. Twist Bioscience Co. has a 52-week low of $15.85 and a 52-week high of $60.90. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of -11.78 and a beta of 1.78.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TWST. Point72 Asset Management L.P. lifted its position in shares of Twist Bioscience by 1,021.8% in the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after purchasing an additional 613,057 shares in the last quarter. Fred Alger Management LLC boosted its stake in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after buying an additional 575,080 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Twist Bioscience by 1.8% during the 3rd quarter. New York State Common Retirement Fund now owns 482,606 shares of the company’s stock valued at $21,804,000 after acquiring an additional 8,529 shares in the last quarter. Driehaus Capital Management LLC increased its stake in shares of Twist Bioscience by 63.0% in the second quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock worth $19,152,000 after acquiring an additional 150,260 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Twist Bioscience by 7.7% in the third quarter. Victory Capital Management Inc. now owns 331,809 shares of the company’s stock worth $14,991,000 after acquiring an additional 23,638 shares during the last quarter.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Barclays reduced their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, The Goldman Sachs Group lifted their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.